Elacestrant vs Taragarestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Elacestrant

Marketed by Stemline Therapeutics, Inc. and partners

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT03778931 · Phase 3 · completed

This was a large randomized trial comparing elacestrant with active standard-of-care treatment, but it was open-label rather than double-blind. The primary progression-free survival endpoints, assessed by blinded imaging review, were statistically significantly better with elacestrant in both ESR1-mutant and all participants, but the lack of participant and investigator blinding limits the strength of the evidence.

Next expected readout: November 2026 · NCT06691035 (registry estimate)

Reported efficacy

Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)); Progression-free Survival in All Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14) (met)

Result source: NCT03778931

Taragarestrant

Developed by InventisBio

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2026 · NCT06954961 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointElacestrantTaragarestrant
PFS, median3.8 vs 1.9vs Standard of Care (SoC)n 115NCT03778931
1 other result
—Trial running · NCT06954961
OS, median—Trial running · NCT06382948—Trial running · NCT06954961
ORR—Trial running · NCT06382948—Trial running · NCT06954961
Clinical benefit rate—Trial running · NCT06382948—Trial running · NCT06954961

PFS, median

Elacestrant
3.8 vs 1.9vs Standard of Care (SoC)n 115NCT03778931
1 other result
Taragarestrant
—Trial running · NCT06954961

OS, median

Elacestrant
—Trial running · NCT06382948
Taragarestrant
—Trial running · NCT06954961

ORR

Elacestrant
—Trial running · NCT06382948
Taragarestrant
—Trial running · NCT06954961

Clinical benefit rate

Elacestrant
—Trial running · NCT06382948
Taragarestrant
—Trial running · NCT06954961
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Taragarestrant: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Elacestrant: 3 of 4 rows · Taragarestrant: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricElacestrant
Dropout rate
36.4%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Discontinued due to AEs
—
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Serious AEs
12.2%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Most frequent reported AEs
nausea 35%
fatigue 19%
vomiting 19%
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Elacestrant

PFS 3.78 vs 1.87 Standard of Care (SoC) months
time to event · months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
2.79 vs 1.91 Standard of Care (SoC) months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
Overall Survival NA vs 16.95 Standard of Care (SoC) months
time to event · months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 1 more result
NA vs NA Standard of Care (SoC) months
NCT03778931 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elacestrant's landscape · Taragarestrant's landscape